Table 2. Subgroup analysis of KRAS mutation status and the prognosis of CRC patients.

Group	Patients amount	KRAS MT vs. KRAS WT
		Multivariate SH model
		HR (95% CI)
All	8,983	1.10 [1.04–1.17]
Stage I	586	1.30 [0.62–2.70]
Stage II	1,278	1.27 [0.95–1.69]
Stage III	2,381	1.28 [1.09–1.49]
Stage IV	4,635	1.14 [1.06–1.23]
Unknown location	257	1.01 [0.69–1.49]
Left	3,476	1.28 [1.15–1.42]
Right	3,593	1.07 [0.97–1.19]
Rectum	1,657	1.23 [1.07–1.43]

Note:

KRAS MT, KRAS mutant; KRAS WT, KRAS wild type; HR, Hazard ratios; 95% CI, 95% confidence intervals; the significant results were bolded.